



# EARNINGS PRESENTATION

4<sup>th</sup> quarter  
and 2025



## Disclaimer

The content of this presentation does not constitute a promise or statement regarding the future performance of the Company. Certain information and conclusions contained herein are related to business prospects, estimate of the Company's operating and financial results and growth prospects.

This information is based on projections related to the Company's management expectations regarding the future of the business and considerations depend on market conditions, regulatory approval, industry performance, exchange rate fluctuations and other risks described in the Company's reports.

Certain percentages and other values included in this document have been rounded to make its presentation easier and chart scales can have different proportions, also to make ease of viewing. Therefore, the numbers and graphs generated may not represent an arithmetic sum and may differ from those presented in financial statements.

This presentation does not constitute an offer or solicitation to purchase shares or any other real estate assets of the Company. The presentation or any information contained herein is not to be used on the basis of a contract or commitment.

The information contained herein is informative and should be understood as such.


Financial  
Results

Market Share  
Evolution



# HIGHLIGHTS


## GLARGINE INSULIN TOTAL MARKET



<b>BIOMM</b>	<b>25%</b>	<b>81%</b>	<b>28%</b>	<b>62%</b>
<b>SANOFI</b>	<b>38%</b>	<b>9%</b>	<b>41%</b>	<b>18%</b>
<b>LILLY</b>	<b>37%</b>	<b>10%</b>	<b>31%</b>	<b>20%</b>

Source: IQVIA



**ENOXAPARINA PRIVATE MARKET**


	4Q24	4Q25	Dec24 - LTM	Dec25 - LTM
<b>BIOMM</b>	3%	4%	3%	4%
EUROFARMA	3%	1%	5%	2%
CRISTALIA	7%	2%	6%	4%
VIATRIS	12%	14%	8%	14%
SANOFI	57%	46%	59%	51%
BLAU	1%	0%	2%	1%
ACHÉ	17%	33%	17%	24%


Source: IQVIA

FINANCIAL  
HIGHLIGHTS



# Net Revenue

R\$ Million




Net revenue reached R\$166.8 million in 4Q25, a positive variation of 317% versus 4Q24, representing the best quarter ever recorded by the Company. In the annual comparison, net revenue reached R\$269.3 million, an increase of 88% compared to 2024, and both positive variations reflect the substantial increase in sales in 2025, mainly from Glargilin



# Gross Profit

R\$ Million




Gross profit reached R\$59.3 million in 4Q25, representing a positive variation of 2,125% compared to 4Q24. Year-on-year, gross profit reached R\$85 million, a 375% increase compared to 2024, and this variation is related to the sales mix, reduced exchange rate, increased productivity, and greater efficiency in the factory




## Operating Expenses

R\$ Million



## Consolidated Ebitda

R\$ Million




Operating expenses reached R\$90.2 million in 2025, a 9% reduction compared to the previous year, reflecting lower marketing expenses. EBITDA, on the other hand, showed the first positive result in the Company's history, ending the year with R\$3.3 million, a reflection of the operational improvement of the company



## Debt Profile

R\$ Million



The Company continues to actively manage its cash flow and its indebtedness profile, attentive to the financing needs of the activities

## **Investor Relations**

Website: <http://ri.biomm.com>

E-mail: [ri@biomm.com](mailto:ri@biomm.com)

## **Press Information**

Agência Máquina

[biomm@agenciamaquina.com](mailto:biomm@agenciamaquina.com)

